Home
  
Corporate Information

Investor Relations

Press Releases

Annual and Quarterly Reports

SEC Filings

Stock Chart

Analyst Coverage

Upcoming Events

Audio Archives

Presentation Archives

FAQ

Email Alerts

Information Request

Corporate Fact Sheet

Product Pipeline
Calendar of Activities
Diabetes Resources
Career Opportunities
Contact Information
Press Releases

Replay
Amylin Pharmaceuticals, Inc. at BIOCOM Investor Conference
October 26, 2009, 9:30 AM PT

Replay
Amylin Pharmaceuticals, Inc. at Credit Suisse Healthcare Conference
November 11, 2009, 10:00 AM PT

Date Title  (click to view the full text)
11/5/2009 Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
11/2/2009 Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
11/1/2009 Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
10/30/2009 BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
10/22/2009 Amylin Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference
10/20/2009 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/19/2009 Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
10/13/2009 Amylin Pharmaceuticals to Webcast Third Quarter Results
9/24/2009 Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
9/10/2009 Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
9/3/2009 Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
8/24/2009 Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
7/21/2009 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/20/2009 Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
7/14/2009 Amylin Pharmaceuticals to Webcast Second Quarter Results
7/9/2009 Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
7/7/2009 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
6/17/2009 Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
6/8/2009 Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
6/7/2009 Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
6/7/2009 Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
6/6/2009 Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
6/3/2009 Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
6/2/2009 Amylin Announces Preliminary Tabulation of Annual Meeting Results
5/29/2009 Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
5/27/2009 Amylin Announces Preliminary Results of Annual Meeting of Stockholders
5/26/2009 Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today
5/20/2009 Amylin Responds to Eastbourne Letter
5/15/2009 Amylin Comments on RiskMetrics Report
5/14/2009 Amylin Issues Statement Regarding Open Letter From Icahn
5/12/2009 Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
5/11/2009 Amylin Sends Letter To Shareholders
5/5/2009 Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
5/4/2009 Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5/1/2009 Amylin Sends Letter to Shareholders
4/29/2009 Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4/23/2009 Amylin Issues Statement in Response to Carl Icahn
4/16/2009 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/9/2009 Amylin Pharmaceuticals to Webcast First Quarter Results
4/2/2009 Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3/31/2009 Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
3/30/2009 Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
3/26/2009 Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
3/10/2009 Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
1/30/2009 Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
1/29/2009 Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
1/27/2009 Amylin Pharmaceuticals Reports 2008 Financial Results
1/26/2009 Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
1/21/2009 Amylin Pharmaceuticals to Webcast Year-End Results
1/12/2009 Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
1/6/2009 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/11/2008 Plans For Exenatide Once Weekly Nda Submission By End Of First Half Of 2009 Reaffirmed Following Fda Feedback
12/8/2008 Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
11/13/2008 Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11/10/2008 Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10/23/2008 Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10/21/2008 Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
10/21/2008 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/15/2008 Amylin Pharmaceuticals to Webcast Third Quarter Results
10/1/2008 Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9/10/2008 First Reported Head-to-Head Study Showed BYETTA® (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia™ (sitagliptin) in Patients With Type 2 Diabetes
8/28/2008 Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
8/26/2008 Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
8/25/2008 Amylin and Lilly Set Date and Time for Conference Call
7/21/2008 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/15/2008 Amylin Pharmaceuticals to Webcast Second Quarter Results
6/9/2008 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
6/9/2008 After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
6/7/2008 Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6/7/2008 Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
6/5/2008 Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6/2/2008 Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
5/23/2008 Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
5/22/2008 Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
5/12/2008 Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5/7/2008 Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
5/5/2008 Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
4/30/2008 Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
4/25/2008 Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
4/21/2008 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/15/2008 Amylin Pharmaceuticals to Webcast First Quarter Results
1/31/2008 Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
1/28/2008 Amylin Pharmaceuticals Reports 2007 Financial Results
1/22/2008 Amylin Pharmaceuticals to Webcast Year-End Results
1/7/2008 PHOTO ADVISORY -- SYMLIN Pen-Injector Devices Now Available
1/7/2008 SYMLIN Pen-Injector Devices Now Available
1/2/2008 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/6/2007 Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
11/30/2007 Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
11/21/2007 Amylin Pharmaceuticals to Present at Research & Development Day
11/15/2007 Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
10/31/2007 Exenatide Once Weekly Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
10/31/2007 Amylin Pharmaceuticals to Webcast Conference Call
10/30/2007 Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
10/29/2007 Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10/17/2007 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/11/2007 Amylin Pharmaceuticals to Webcast Third Quarter Results
10/1/2007 FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
9/14/2007 Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
8/31/2007 Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8/7/2007 Amylin Resale Registration Statement Declared Effective by SEC
7/23/2007 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/16/2007 Amylin Pharmaceuticals to Webcast Second Quarter Results
6/25/2007 BYETTA offers added benefits of progressive weight loss and improved beta cell function in an analysis of the longest extension study to date
6/24/2007 BYETTA® Study Showed Comparable Blood Glucose Control to Insulin
6/23/2007 SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
6/23/2007 BYETTA(R) Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
6/19/2007 Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
6/8/2007 Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference
6/6/2007 Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes
6/5/2007 Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes
6/4/2007 Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
5/24/2007 Amylin Pharmaceuticals to Present at Banc of America Healthcare Conference
5/17/2007 Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
4/26/2007 Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4/16/2007 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/9/2007 Amylin Pharmaceuticals to Webcast First Quarter Results
3/14/2007 Delta Burke to Americans: Let's Talk about Managing Diabetes
3/13/2007 Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
3/8/2007 Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
3/6/2007 Amylin Pharmaceuticals Elects Teresa Beck to Board of Directors
2/20/2007 New Storage Instructions Approved for BYETTA(R)
2/6/2007 Amylin Pharmaceuticals Appoints Marcea Bland Lloyd Senior Vice President and General Counsel
1/31/2007 Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
1/30/2007 Amylin Pharmaceuticals Reports 2006 Financial Results
1/30/2007 Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury as Chief Executive Officer Effective March 1, 2007
1/23/2007 Amylin Pharmaceuticals to Webcast Year-End Results
1/3/2007 FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
1/2/2007 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/22/2006 FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
11/24/2006 Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
11/21/2006 BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
11/9/2006 Amylin Pharmaceuticals to Present at BIOCOM Investor Conference and Credit Suisse Healthcare Conference
11/1/2006 Amylin Pharmaceuticals to Present at Cowen and Company Global Health Care Conference
10/24/2006 Amylin Pharmaceuticals Expands Clinical Program in Obesity
10/20/2006 Amylin Pharmaceuticals to Present at First Annual Research & Development Breakfast
10/18/2006 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/12/2006 Amylin Pharmaceuticals to Webcast Third Quarter Results
10/3/2006 Amylin Pharmaceuticals Appoints Joe Young Sr. Vice President, Marketing
9/22/2006 Amylin Pharmaceuticals to Present at UBS Warburg Global Life Science Conference
9/21/2006 Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes
9/16/2006 New study shows exenatide improves blood sugar levels as effectively
9/15/2006 Amylin Pharmaceuticals to Present at Nordea Novel Anti-Diabetics Seminar, Oppenheimer Diabetes Conference and Merrill Lynch Global Conference
9/14/2006 Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
9/14/2006 Study demonstrated once-weekly exenatide LAR improved glucose control in patients with type 2 diabetes
9/7/2006 SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
9/1/2006 Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8/24/2006 Amylin Pharmaceuticals, Inc. Announces Conversion of All Outstanding 2.25% Convertible Senior Notes Due 2008
7/24/2006 Amylin Pharmaceuticals, Inc. Announces Details of Redemption of 2.25% Convertible Senior Notes Due June 30, 2008
7/24/2006 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/21/2006 Amylin Pharmaceuticals Announces BYETTA Revenue
7/17/2006 Amylin Pharmaceuticals to Webcast Second Quarter Results
6/20/2006 Amylin Pharmaceuticals to Present at William Blair Growth Stock Conference and Piper Jaffray European Healthcare Conference
6/10/2006 BYETTA(R) Shown to Reduce Blood Glucose Levels When Added to Patients Using a TZD
6/10/2006 Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
6/10/2006 BYETTA(R) Extension Study Shows Sustained Improvements in Blood Glucose Control and Progressive Weight Loss After Two Years
6/10/2006 Late Breaking Data at ADA 2006 Shows Amylin-Leptin Co-Administration Reduces Body Weight and Body Fat in Animal Studies
6/10/2006 New Study Illustrates Economic Benefit of Weight Loss in People with Type 2 Diabetes
6/9/2006 Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6/7/2006 Amylin Pharmaceuticals Promotes Daniel M. Bradbury to President and Chief Operating Officer
6/6/2006 Amylin Pharmaceuticals Demonstrates Progress Across Diabetes and Obesity Portfolios at ADA 2006
5/25/2006 Amylin Pharmaceuticals to Present at Friedman Billings Ramsey Growth Conference
5/10/2006 Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders and Bank of America Health Care Conference
5/1/2006 Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
4/26/2006 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/20/2006 Amylin Pharmaceuticals Announces BYETTA Revenue
4/4/2006 Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
3/30/2006 Amylin Pharmaceuticals Announces Public Offering of Common Stock
3/28/2006 Amylin Pharmaceuticals Elects Steven Altman to Board of Directors
3/27/2006 Amylin Pharmaceuticals Announces Public Offering of Common Stock
3/24/2006 Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes Initiated
3/2/2006 Amylin Pharmaceuticals to Present at Cowen & Co. Health Care Conference and Lehman Brothers Global Healthcare Conference
3/1/2006 Supplemental New Drug Application for BYETTA Submitted to FDA for Use With TZDs
2/22/2006 Amylin Pharmaceuticals to Present at Citigroup Healthcare Conference
2/9/2006 Amylin Pharmaceuticals Reports 2005 Financial Results
2/9/2006 Pramlintide Obesity Study Results Positive
2/2/2006 Amylin Pharmaceuticals to Webcast Year-End Results
1/26/2006 Amylin Pharmaceuticals Announces BYETTA Revenue
1/9/2006 Amylin Pharmaceuticals Added to the NASDAQ-100 Index
1/3/2006 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/29/2005 Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR
12/22/2005 Amylin Recognized for Biotechnology Leadership and Product Innovation
12/21/2005 Amylin Pharmaceuticals Elects Dr. James Gavin to Board of Directors
11/15/2005 BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients Treated With TZDs
11/10/2005 Amylin Pharmaceuticals to Present at Lehman Brothers Small Cap Conference
10/26/2005 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/20/2005 Amylin Pharmaceuticals to Webcast Third Quarter Results
9/28/2005 Amylin Pharmaceuticals Elects Karin Eastham to Board of Directors
9/22/2005 Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference
9/19/2005 Amylin Pharmaceuticals Appoints Roger Marchetti as Senior Vice President of Human Resources and Corporate Services
9/12/2005 Study shows exenatide improves blood sugar levels
9/12/2005 Long-term data on exenatide show sustained improvements in glucose control and progressive weight reduction in people with type 2 diabetes
9/9/2005 Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference
9/2/2005 Amylin Pharmaceuticals to Present at Oppenheimer Diabetes Conference, Thomas Weisel Healthcare Tailwinds Conference and Biocentury Newsmakers Conference
8/30/2005 Amylin Pharmaceuticals Announces Public Offering of Common Stock
8/22/2005 Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control
8/4/2005 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/29/2005 Amylin Pharmaceuticals to Webcast Second Quarter Results
6/23/2005 Amylin Pharmaceuticals to Present at Bear Stearns Boston Biotech Confab and Friedman Billings Ramsey European Investor Conference
6/10/2005 Long-Term Data on BYETTA(TM) Show Sustained Improvements in Glucose Control and Progressive Weight Reduction in People with Type 2 Diabetes
6/10/2005 Study Shows BYETTA(TM) Improves Blood Sugar Levels as Effectively as Insulin Glargine
6/9/2005 Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6/9/2005 Newly Approved First-in-Class Treatment for Type 2 Diabetes Is Now Available
6/6/2005 Amylin Pharmaceuticals Announces Presentation of 12 Abstracts at the American Diabetes Association Annual Meeting
6/3/2005 Amylin Presents Results From Pramlintide Obesity Program at 14th Annual European Congress on Obesity
5/20/2005 Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders and Presentation
5/13/2005 Amylin Pharmaceuticals to Present at Banc of America Securities' Health Care Conference
5/4/2005 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/29/2005 Amylin Pharmaceuticals to Webcast First Quarter Results and Morgan Stanley Global Healthcare Unplugged Conference Presentation
4/29/2005 Amylin and Lilly Announce FDA Approval of BYETTA(TM) (Exenatide) Injection
3/25/2005 Amylin Pharmaceuticals to Present at Smith Barney Citigroup Healthcare Conference and Lehman Brothers Global Healthcare Conference
3/16/2005 Amylin Pharmaceuticals Announces FDA Approval of SYMLIN(R) for Insulin-Using Type 2 and Type 1 Diabetes
3/2/2005 Amylin Pharmaceuticals Reports 2004 Financial Results
2/24/2005 Amylin Pharmaceuticals to Webcast Year-End Results
2/7/2005 Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
1/27/2005 Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
1/21/2005 Amylin Pharmaceuticals to Present at Piper Jaffray Health Care Conference
1/21/2005 Amylin Pharmaceuticals Announces Public Offering of Common Stock
1/18/2005 Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
1/5/2005 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/5/2004 Amylin Pharmaceuticals Provides Update On Clinical Development Programs
12/1/2004 Amylin Pharmaceuticals to Webcast Corporate Update
11/2/2004 Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005
11/2/2004 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/26/2004 Amylin Pharmaceuticals to Webcast Third Quarter Results
9/22/2004 Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference
9/20/2004 Amylin Pharmaceuticals Submits Complete Response to FDA for SYMLIN(R)
9/17/2004 Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory Status
9/15/2004 Amylin Pharmaceuticals to Present at Punk Ziegel Diabetes Symposium
9/8/2004 Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference
9/3/2004 Amylin Pharmaceuticals to Present at Goldman Sachs Therapeutic Conference
9/2/2004 Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare Conference and BioCentury NewsMakers Conference
9/1/2004 Exenatide New Drug Application Accepted for Review by the FDA
8/5/2004 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/30/2004 Amylin Pharmaceuticals to Webcast Second Quarter Results
7/26/2004 Successful Completion of Study Comparing Exenatide to Insulin Glargine Results in Milestone Payment from Lilly to Amylin
6/30/2004 New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes
6/6/2004 Scientific Presentations of Exenatide Data Show Improvements in Glucose Control and Restored Insulin Response in People with Type 2 Diabetes
6/5/2004 Late-Breaking Presentation of Exenatide Pivotal Studies Show Significant Improvements in Glucose Control With Associated Weight Loss in People With Type 2 Diabetes
6/3/2004 Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6/2/2004 Amylin Pharmaceuticals to Webcast Data Presented at American Diabetes Association Annual Meeting
5/21/2004 Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for Publication at the American Diabetes Association Annual Meeting
5/14/2004 Amylin Files Resale Registration Statement for Convertible Senior Notes
5/13/2004 Amylin Pharmaceuticals to Present at Banc of America Securities Healthcare Conference
5/3/2004 Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders Presentation
4/30/2004 Amylin Pharmaceuticals To Present At Morgan Stanley Healthcare Conference
4/28/2004 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/21/2004 Amylin Pharmaceuticals to Webcast First Quarter Results
4/8/2004 Amylin Pharmaceuticals to Co-promote Reliant Pharmaceuticals' Family of Cardiovascular Products
4/5/2004 Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes
3/31/2004 Amylin Pharmaceuticals, Inc. Announces Pricing Of Convertible Senior Notes
3/30/2004 Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
3/30/2004 Amylin Pharmaceuticals Advances Clinical Pipeline in Diabetes and Obesity
2/27/2004 Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
2/24/2004 Amylin Pharmaceuticals Reports 2003 Financial Results
2/19/2004 Amylin Pharmaceuticals to Webcast Year-End Results
2/12/2004 Amylin Pharmaceuticals to Present At Roth Capital Partners Growth Stock Conference
1/22/2004 Amylin Pharmaceuticals to Present at U.S. Bancorp Piper Jaffray Healthcare Conference
1/12/2004 Amylin Pharmaceuticals CEO to Provide Corporate Update at JPMorgan Healthcare Conference
1/9/2004 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
1/7/2004 Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R)
1/6/2004 Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
12/19/2003 Amylin Pharmaceuticals Announces Informal Inquiry by the Securities and Exchange Commission
12/18/2003 Amylin and Lilly Announce Achievement of First Exenatide Development Milestones
12/18/2003 Amylin Pharmaceuticals to Webcast Corporate Update Conference Call
12/17/2003 Amylin Pharmaceuticals Receives Second Approvable Letter for SYMLIN(R)
12/11/2003 Amylin Pharmaceuticals Files Shelf Registration Statement
11/24/2003 Amylin Pharmaceuticals to Webcast Corporate Update Conference Call
11/24/2003 Positive Results from Final Exenatide Pivotal Study Mark Successful Completion of Phase 3
11/10/2003 Exenatide Continues to Generate Positive Results in Second of Three Phase 3 Studies
11/4/2003 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/31/2003 Amylin Pharmaceuticals Names Michael Hanley As Vice President of Discovery Research
10/30/2003 Amylin Pharmaceuticals to Webcast Third Quarter Company Update Conference Call
9/29/2003 Amylin Resale Registration Statement Declared Effective by SEC
9/18/2003 Amylin Pharmaceuticals to Present at 2003 Morgan Stanley Convertible Conference and UBS Global Life Sciences Conference
9/15/2003 Amylin Pharmaceuticals Elects Joseph P. Sullivan to Board of Directors
9/3/2003 Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference And Roth Capital Partners New York Conference
8/29/2003 Amylin Pharmaceuticals to Present at BioCentury Newsmakers Conference And Thomas Weisel Healthcare Conference
8/25/2003 Exenatide Open-Label Study Continues to Show Promise for People With Type 2 Diabetes
8/21/2003 Amylin Pharmaceuticals Announces Plans for 18th Congress of the International Diabetes Federation
8/15/2003 Amylin Files Resale Registration Statement for Convertible Senior Notes
8/14/2003 Amylin Pharmaceuticals Reports Second Quarter Financial Results
8/11/2003 Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
8/6/2003 First of Three Phase 3 Exenatide Studies Achieves Positive Results in Type 2 Diabetes
7/29/2003 Amylin Pharmaceuticals Reports Encouraging Phase 2 Results From GLP-1 Program In Severe Congestive Heart Failure
7/21/2003 Amylin Pharmaceuticals Repays Johnson & Johnson Loans From Prior SYMLIN(R) Collaboration
7/18/2003 Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes
7/14/2003 Amylin Pharmaceuticals Joins the Russell 1000(R) Index
7/14/2003 Amylin Pharmaceuticals Appoints Joni Harvey As Vice President of Quality Assurance
7/8/2003 Data From Two Exenatide Studies Demonstrate Potential For the Treatment of Type 2 Diabetes
6/18/2003 Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes
6/16/2003 Amylin Pharmaceuticals Submits New Drug Application Amendment for SYMLIN(R) For the Treatment of Diabetes
6/16/2003 Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
6/15/2003 Exenatide Open-Label Study Shows Encouraging Results in People With Type 2 Diabetes
6/12/2003 Amylin Pharmaceuticals to Webcast Investor Update From American Diabetes Association Annual Meeting
6/9/2003 Amylin Pharmaceuticals Names New Chief Executive Officer
6/6/2003 Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6/2/2003 Exenatide Open-Label Data Accepted for Late-Breaking Presentation at American Diabetes Association Annual Meeting
6/2/2003 Amylin Pharmaceuticals Announces Plans For American Diabetes Association Annual Meeting
5/22/2003 Amylin Pharmaceuticals Expands Marketing and Sales Management Team
5/19/2003 Amylin Pharmaceuticals Reports Data From SYMLIN(R) Dose-Titration Study
5/7/2003 Amylin Pharmaceuticals Reports First Quarter Financial Results
5/2/2003 Amylin Pharmaceuticals to Webcast First Quarter Company Update Conference Call
4/28/2003 Amylin Pharmaceuticals to Present At Morgan Stanley's Healthcare Unplugged Conference
3/31/2003 Amylin Pharmaceuticals Submits Additional SYMLIN(R) Information to theSwiss Regulatory Authorities
3/24/2003 Amylin Pharmaceuticals to Present At Banc of America Securities Healthcare Conference
3/19/2003 Amylin, Lilly and Alkermes Announce Preliminary Phase 2 Results and Submission Of IND for Exenatide LAR (Sustained Release) Program in Type 2 Diabetes
3/13/2003 Amylin Pharmaceuticals to Present at Roth Capital Partners Growth Stock Conference
2/27/2003 Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
2/20/2003 Amylin Pharmaceuticals Reports 2002 Financial Results
2/13/2003 Amylin Pharmaceuticals to Webcast Fourth Quarter Company Update Conference Call
1/29/2003 Amylin Pharmaceuticals Completes Acquisition of Rights To Phase 2 GLP-1 Program for Congestive Heart Failure
1/22/2003 Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
1/17/2003 Amylin Pharmaceuticals Announces Public Offering of Common Stock
1/10/2003 Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
1/6/2003 Amylin and Lilly Announce Completion of Enrollment for Remaining Two Phase 3 Pivotal Trials of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
1/2/2003 Amylin Pharmaceuticals to Present at JP Morgan H&Q Healthcare Conference
12/26/2002 Amylin Pharmaceuticals to Acquire Rights to Phase 2 GLP-1 Program For Cardiovascular Indication
12/18/2002 Amylin and Lilly Announce Encouraging Results From Open-Label Study of AC2993 (Synthetic Exendin-4) in People With Type 2 Diabetes
12/2/2002 Amylin Pharmaceuticals Elects Thomas R. Testman to Board of Directors
11/18/2002 Amylin Pharmaceuticals Announces Filing of Shelf Registration Statement
11/5/2002 Amylin Pharmaceuticals to Present at Wall Street Analyst Forum
10/29/2002 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/28/2002 Amylin and Lilly Announce Completion of Enrollment for First Phase 3 Pivotal Trial of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
10/23/2002 Amylin Pharmaceuticals Revises European Regulatory Plans for SYMLIN
10/22/2002 Amylin Pharmaceuticals to Webcast Third Quarter Company Update Conference Call
10/4/2002 Amylin Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference
9/20/2002 Lilly and Amylin To Collaborate on Potential Breakthrough Diabetes Treatment
9/19/2002 Amylin Pharmaceuticals to Webcast Conference Call for Analysts and Investors
9/5/2002 Amylin Pharmaceuticals Completes Enrollment For SYMLIN(TM) Dose Titration Study
8/12/2002 Amylin Pharmaceuticals Reports Second Quarter Financial Results
8/6/2002 Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
6/25/2002 Amylin Pharmaceuticals Initiates First Phase 2 Study of Long-Acting Release Formulations of AC2993 (Synthetic Exendin-4) in People With Type 2 Diabetes
6/18/2002 Amylin Pharmaceuticals Adopts Stockholder Rights Plan
6/17/2002 Amylin Pharmaceuticals Hosts Diabetes Summit Focused on the Hormone Glucagon And Its Role in Glucose Control
6/17/2002 Amylin Pharmaceuticals Provides Expanded Analyses of AC2993 (Synthetic Exendin-4) Phase 2 Data in Two Oral Presentations At American Diabetes Association Annual Meeting
6/14/2002 Amylin Pharmaceuticals Announces New Transfer Agent and Registrar
6/13/2002 Amylin Pharmaceuticals Appoints Tony Chin as Vice President of Quality Assurance
6/12/2002 Amylin Pharmaceuticals CEO Provides Corporate Update at Goldman Sachs Healthcare Conference
6/12/2002 Amylin Pharmaceuticals to Present at American Diabetes Association Annual Meeting
6/11/2002 Amylin Pharmaceuticals Announces New Phase 1 Data On Atherosclerosis Drug Candidate, AC3056
6/6/2002 Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference
5/14/2002 Amylin Pharmaceuticals to be Added to Nasdaq Biotechnology Index
5/8/2002 Amylin Pharmaceuticals Reports First Quarter Financial Results
5/1/2002 Amylin Pharmaceuticals to Webcast First Quarter Company Update Conference Call
4/15/2002 Amylin Pharmaceuticals Initiates Dose Titration Study for SYMLIN(TM) In Patients With Type 1 Diabetes
3/28/2002 Amylin Pharmaceuticals to Present At Banc of America Securities Healthcare Conference
3/14/2002 Amylin Pharmaceuticals Initiates Third Phase 3 Pivotal Trial Of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
3/11/2002 Amylin Pharmaceuticals Elects James N. Wilson to Board of Directors
2/21/2002 Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
2/21/2002 Amylin Pharmaceuticals Reports 2001 Financial Results
2/19/2002 Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option By Underwriters
2/14/2002 Amylin Pharmaceuticals to Webcast Fourth Quarter Company Update Conference Call
2/13/2002 Amylin Pharmaceuticals to Present at Roth Capital Partners Growth Stock Conference
2/11/2002 Amylin Pharmaceuticals Announces Public Offering of Common Stock
1/30/2002 Amylin Pharmaceuticals Initiates Second Phase 3 Pivotal Trial of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
1/28/2002 Amylin Pharmaceuticals to File Preliminary Prospectus Supplement For Public Offering of Common Stock
1/9/2002 Amylin Pharmaceuticals Reports Improved Daily Glucose Profiles In Type 1 Diabetes With SYMLIN(TM) Therapy
1/3/2002 Amylin Pharmaceuticals Announces Positive Results From Continuous Infusion Study of AC2993 (Synthetic Exendin-4)
12/27/2001 Amylin Pharmaceuticals Announces Plan to Submit SYMLIN(TM) NDA Amendment in Second Half of 2002
12/26/2001 Amylin Pharmaceuticals to Webcast Update on SYMLIN(TM) Regulatory Plans
12/13/2001 Amylin Pharmaceuticals Announces Filing of Shelf Registration Statement
12/10/2001 Amylin Pharmaceuticals Initiates First Phase 3 Pivotal Trial of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
12/5/2001 Amylin Pharmaceuticals Announces Two Abstracts Accepted by American Society For Clinical Pharmacology and Therapeutics for 2002 Annual Meeting
11/6/2001 Amylin Pharmaceuticals Reports Third Quarter Financial Results
11/1/2001 Amylin Pharmaceuticals to Webcast Third Quarter Company Update Conference Call
10/26/2001 Amylin Pharmaceuticals to Present At Salomon Smith Barney Health Care Conference
10/12/2001 Amylin Pharmaceuticals Elects Terrance H. Gregg to Board of Directors
10/12/2001 Amylin Pharmaceuticals Confirms Plan to Initiate Phase 3 Program for Diabetes Drug Candidate, AC2993, by Year End
10/12/2001 Amylin Pharmaceuticals Receives FDA Approvable Letter for SYMLIN(TM) For Type 1 and Type 2 Diabetes
10/8/2001 Amylin Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference
9/25/2001 Amylin Pharmaceuticals Appoints Lloyd A. Rowland as Vice President And General Counsel
9/19/2001 Amylin Pharmaceuticals Reports Positive Effects on Fasting Glucose From a Phase 2 Study of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
9/17/2001 Amylin Pharmaceuticals Reschedules Corporate Update Conference Call With Analysts and Investors
9/12/2001 Amylin Pharmaceuticals Postpones Corporate Update Conference Call With Analysts and Investors
9/11/2001 Amylin Pharmaceuticals Presents at European Diabetes Conference In Glasgow, Scotland
9/11/2001 Amylin Pharmaceuticals to Webcast Corporate Update Conference Call With Analysts and Investors
8/14/2001 Amylin Pharmaceuticals Reports Second Quarter Financial Results
8/13/2001 Amylin Pharmaceuticals and Alkermes Demonstrate Extended Release in Initial Phase 1 Study of Long-Acting Formulations of AC2993 (Synthetic Exendin-4)
8/10/2001 Amylin Pharmaceuticals Reports Positive Interim Results From a Phase 2 Study Of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
8/9/2001 Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
8/3/2001 Amylin Pharmaceuticals Provides Corporate Update At Adams, Harkness & Hill 21st Annual Summer Seminar
8/1/2001 Amylin Pharmaceuticals to Present at Adams, Harkness and Hill 21st Annual Summer Seminar
7/26/2001 FDA Advisory Committee Votes Not to Recommend Approval of SYMLIN for Use In Type 1 and Insulin-Using Type 2 Diabetes
7/26/2001 Amylin Pharmaceuticals Announces Conference Call to Discuss FDA Advisory Committee Recommendations
7/25/2001 FDA Posts Briefing Documents for SYMLIN(TM) Advisory Committee Meeting
6/24/2001 Amylin Pharmaceuticals Presents Positive Results from AC2993 (synthetic exendin-4) One-Month Study in Type 2 Diabetes at American Diabetes Association Annual Meeting
6/20/2001 Amylin Pharmaceuticals Announces Positive Results From AC2993 (Synthetic Exendin-4) Phase 2 Study in Type 2 Diabetes
6/14/2001 Amylin Pharmaceuticals to Present at Wells Fargo Van Kasper Growth Stock Conference
6/12/2001 Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference
5/31/2001 Amylin Pharmaceuticals Submits European Marketing Authorization Applications for SYMLIN(TM)
5/30/2001 Amylin Pharmaceuticals Successfully Closes $41 Million Private Placement of Common Stock
5/14/2001 Amylin Pharmaceuticals to Present SYMLIN(TM) to FDA Advisory Committee in July
5/14/2001 Amylin Pharmaceuticals Reports First Quarter Financial Results
5/14/2001 Amylin Pharmaceuticals Announces $41 Million Private Placement of Common Stock
5/8/2001 Amylin Pharmaceuticals to Webcast First Quarter Company Update Conference Call
3/26/2001 Amylin Pharmaceuticals and Alkermes Initiate Clinical Study of Long-Acting Formulation of AC2993 (Synthetic Exendin-4)
3/19/2001 Amylin Pharmaceuticals Obtains License From NIH for Novel Use of Exendin-4
2/27/2001 Amylin Pharmaceuticals Reports 2000 Financial Results
2/22/2001 Amylin Pharmaceuticals Announces Company Update Call for 4Q 2000 And Presentation at Upcoming Investor Conference
2/16/2001 Amylin Pharmaceuticals to Webcast Presentation at Upcoming Investor Conference
2/2/2001 Amylin Pharmaceuticals Announces Departure Of Donald H. Rumsfeld From Board of Directors
1/25/2001 Amylin Pharmaceuticals Announces SYMLIN™ New Drug Application Accepted for Review by the Food and Drug Administration
1/12/2001 Amylin Pharmaceuticals CEO Provides Corporate Update at JP Morgan H&Q Healthcare Conference
1/5/2001 Amylin Pharmaceuticals to Webcast Presentation at Upcoming Investor Conference
12/18/2000 Amylin Pharmaceuticals' Board of Directors Approves SYMLIN™ Commercialization Plan
12/7/2000 Amylin Pharmaceuticals Submits New Drug Application for SYMLIN™ for Treatment of Diabetes
11/6/2000 Amylin Pharmaceuticals Reports Third Quarter Financial Results
11/2/2000 Amylin Pharmaceuticals Initiates Phase 2 Study of Diabetes Drug Candidate AC2993 in Type 2 Diabetes to Support Start of Phase 3 in 2001
10/30/2000 Amylin Pharmaceuticals to Webcast Third Quarter Company Update and Upcoming Investor Presentation
10/17/2000 Amylin Pharmaceuticals Announces Successful Completion of AC2993 LAR Feasibility Work with Alkermes and Plans for Human Studies in 2001
10/2/2000 Amylin Pharmaceuticals Announces Completion of Initial Phase 1 Study of Atherosclerosis/Restenosis Drug Candidate, AC3056
9/14/2000 Amylin Pharmaceuticals to Present at International Diabetes Meeting This Week in Jeruslem, Israel
8/14/2000 Amylin Pharmaceuticals Reports Second Quarter Financial Results and Addition to Russell U.S. Equity Indexes
6/9/2000 Amylin Pharmaceuticals Reports Preliminary Results From a Phase 2 Study of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
6/5/2000 Amylin Pharmaceuticals Appoints Daniel M. Bradbury and Julia R. Brown to Executive Vice President Positions
6/1/2000 Amylin Pharmaceuticals Announces Initiation of Phase 1 Clinical Study for Atherosclerosis/Restenosis Drug Candidate
5/15/2000 Amylin Pharmaceuticals Reports First Quarter Financial Results and Progress on SYMLIN NDA Submission
5/15/2000 Amylin Pharmaceuticals and Alkermes Sign Agreement for Development of Long-Acting Formulation of AC2993 (Synthetic Exendin-4)
3/31/2000 Amylin Pharmaceuticals Appoints Mark G. Foletta as Vice President of Finance and Chief Financial Officer
3/27/2000 Amylin Pharmaceuticals Reports 1999 Financial Results
2/22/2000 Amylin Pharmaceuticals Completes $100 Million Private Stock Sale
2/8/2000 Amylin Pharmaceuticals Announces Return to Nasdaq National Market
1/10/2000 Amylin Pharmaceuticals Announces Cardiovascular Risk Factor Reduced by AC2993 (synthetic exendin-4)
1/7/2000 Amylin Pharmaceuticals Announces Results From a New Dose-Finding Phase 2 Study of AC2993 (synthetic exendin-4)
12/9/1999 Amylin Pharmaceuticals Appoints Alain D. Baron, M.D. Vice President, Clinical Research
11/8/1999 Amylin Pharmaceuticals Reports Positive Results for SYMLIN in US Type 1 Diabetes Study
11/5/1999 Amylin Pharmaceuticals Reports Third Quarter Financial Results
10/28/1999 Amylin Pharmaceuticals Reports Positive Phase 2 Study of AC2993 (synthetic exendin-4) in People with Type 2 Diabetes
10/7/1999 Amylin Pharmaceuticals Raises $18.5 Million in Private Sale of Stock
9/30/1999 Researchers at the National Institute on Aging and Massachsetts General Hospital Report Enhanced Insulin Response Following Exendin-4 Administration in People with Type 2 Diabetes
9/22/1999 Amylin Pharmaceuticals Elects Donald H. Rumsfeld to Board of Directors
9/13/1999 Amylin Pharmaceuticals Grants Exclusive License to Linco Research for Amylin-Developed Proprietary Antibodies
9/13/1999 Amylin Pharmaceuticals Announces Conversion of Series A Preferred Stock to Common Stock
8/31/1999 Amylin Pharmaceuticals Reports Positive Results for SYMLIN™ in US Type 2 Diabetes Study
8/31/1999 Amylin Pharmaceuticals Elects Former American Diabetes Association President Jay S. Skyler, MD as Board Member
8/23/1999 Amylin Pharmaceuticals Acquires Patent Rights for Exendin-4 Gene
8/12/1999 Amylin Pharmaceuticals Appoints Joann L. Data, M.D., Ph.D. Senior Vice President, Regulatory Affairs and Quality Assurance
8/9/1999 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/14/1999 Amylin Pharmaceuticals Elects Former Eli Lilly CEO Vaughn D. Bryson as Board Member
6/30/1999 Amylin Pharmaceuticals Begins Phase 2, Multiple-Dose Study of AC2993 (Synthetic Exendin-4) in People with Type 2 Diabetes
5/17/1999 Amylin Pharmaceuticals Reports First Quarter Financial Results
5/4/1999 Amylin Pharmaceuticals Receives $2.6 Million from Sale of Its Cabrillo Laboratories Division To Magellan
4/30/1999 Amylin Pharmaceuticals Reports Successful Study of Second Diabetes Drug Candidate AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
4/27/1999 Amylin Pharmaceuticals Announces Trademark Selection and Contracts with CP Pharmaceuticals for Manufacture of Injection Cartridges for Diabetes Drug Candidate, Pramlintide
3/31/1999 Amylin Pharmaceuticals Reports 1998 Financial Results
3/24/1999 Amylin Pharmaceuticals Raises $15 Million from Private Sale of Stock
3/3/1999 Amylin Pharmaceuticals Begins Study of AC2993 (Synthetic Exendin-4) in People with Type 2 Diabetes
2/9/1999 Amylin Pharmaceuticals Signs Letter of Intent for Sale of Its Cabrillo Laboratories Division to Magellan Laboratories
1/29/1999 Amylin Pharmaceuticals Common Stock to Trade on the Nasdaq Smallcap Market
1/25/1999 Amylin Pharmaceuticals Announces Additional Data from Long-Term Pramlintide Studies
1/13/1999 Amylin Pharmaceuticals Files IND for AC2993 (Synthetic Exendin-4); Reports on Feasibility of Non-Injectable Routes of Delivery
1/12/1999 Amylin Pharmaceuticals Announces the Creation of a New Division, Cabrillo Laboratories
10/20/1998 Amylin Pharmaceuticals Announces Results for Diabetes Drug from Two Phase 3 Studies
10/20/1998 Amylin Pharmaceuticals Reports Successful Phase 1 Study of Exendin-4, Diabetes Drug Candidate
10/20/1998 Amylin Pharmaceuticals Reports Third Quarter Financial Results
8/18/1998 Amylin Pharmaceuticals Begins First Human Study of Exendin-4, Its Second Diabetes Drug Candidate
8/10/1998 Amylin Pharmaceuticals Reports Second Quarter Financial Results
7/29/1998 Amylin Pharmaceuticals Raises $13 Million from Stock Offering To Investors, Company Executives
7/10/1998 Amylin Pharmaceuticals Completes Enrollment in U.S. for Its Phase III Clinical Studies of Pramlintide
7/10/1998 Amylin Pharmaceuticals Files Registration Statement for Common Stock Offering
5/13/1998 Amylin Pharmaceuticals Reports First Quarter Financial Results
3/26/1998 Amylin Pharmaceuticals Names Joseph C. Cook, Jr. as Chairman and Chief Executive Officer
3/19/1998 Amylin Pharmaceuticals Completes Enrollment in Europe And Canada for Pramlintide Phase III Clinical Studies
3/2/1998 Amylin Pharmaceuticals Announces that Johnson & Johnson Plans to Withdraw from Collaboration in Six Months
3/2/1998 Amylin Pharmaceuticals Reports 1997 Financial Results
2/5/1998 Amylin Pharmaceuticals to Screen Chemical Library from ChemDiv for Metabolic Drugs
1/8/1998 Amylin Pharmaceuticals Announces CFO Plans to Step Down
11/11/1997 Amylin Pharmaceuticals Announces Third Quarter Financial Results and Expansion of Diabetes Development Program
11/3/1997 Amylin Pharmaceuticals and SIDDCO Enter into Agreement to Discover Metabolic Drugs
10/1/1997 Amylin Pharmaceuticals Raises $30.6 Million in Debt Financing from Johnson & Johnson
8/15/1997 Amylin Pharmaceuticals Announces Initial Phase III Results are Positive in Type 1 Diabetes and Encouraging in Type 2 Diabetes
8/11/1997 Amylin Pharmaceuticals Reports Second Quarter Financial Results
8/5/1997 Amylin Pharmaceuticals to Screen Chemical Library from Tripos and Panlabs for Metabolic Drugs
6/24/1997 Amylin Pharmaceuticals Begins Testing New Indication for Diabetes Drug Candidate
6/23/1997 Amylin Pharmaceuticals and Johnson and Johnson Expand Product Development Pact Again
6/9/1997 Amylin Pharmaceuticals Announces Management Promotions
5/6/1997 Amylin Pharmaceuticals Reports First Quarter Financial Results
4/1/1997 Amylin Pharmaceuticals Acquires Rights to Novel Lipid-Lowering Agents from Hoechst Marion Roussel
3/19/1997 Amylin Pharmaceuticals and Johnson & Johnson Expand Collaboration
3/4/1997 Amylin Pharmaceuticals Announces Management Promotions
2/27/1997 Amylin Pharmaceuticals Reports 1996 Financial Results
1/8/1997 Amylin Pharmaceuticals Announces Positive Clinical Results in Mixing its Experimental Diabetes Drug with Insulin
12/19/1996 Amylin Pharmaceuticals Initiates Final Pivotal Studies of Diabetes Drug Candidate
11/14/1996 Amylin Pharmaceuticals Reports Third Quarter Financial Results
11/1/1996 Amylin Pharmaceuticals to Net $31.2 Million from Sales of Common Stock to the Public, Company Executives, and Johnson & Johnson
10/16/1996 Amylin Pharmaceuticals Acquires Rights to Third, Complementary, Potential Diabetes Drug Technology
10/16/1996 Amylin Pharmaceuticals Plans to Sell $35 Million of CommonStock to the Public and Johnson & Johnson
10/7/1996 Amylin Pharmaceuticals Acquires Rights to Potential Diabetes Drug Derived from Gila Monster Venom
9/19/1996 Amylin Pharmaceuticals Announces Management Changes
8/9/1996 Amylin Pharmaceuticals Reports Second Quarter Financial Results
8/7/1996 Amylin Pharmaceuticals Achieves $22 Million Milestone in Collaboration with Johnson & Johnson
8/7/1996 Amylin Pharmaceuticals Announces Positive Phase II Clinical Results in Insulin-Using Type II Diabetes
7/17/1996 Amylin Pharmaceuticals Elects New President and CEO
6/12/1996 Amylin Pharmaceuticals Completes Enrollment in Clinical Trials of Diabetes Drug Candidate
5/3/1996 Amylin Pharmaceuticals Reports First Quarter Financial Results
2/14/1996 Amylin Pharmaceuticals Reports 1995 Financial Results; European Patent Allowance
1/10/1996 Amylin Pharmaceuticals Recruits Senior Vice President of Research from Hoechst Marion Roussel
11/20/1995 Amylin Pharmaceuticals Announces Board Additions and Management Change
11/6/1995 Amylin Pharmaceuticals Announces Third Quarter Results
9/22/1995 Amylin Pharmaceuticals Raises $30 Million in Common Stock Offerings
9/1/1995 Amylin Pharmaceuticals File Public Offering For 3.77 Million Shares of Common Stock
8/28/1995 Amylin Pharmaceuticals Reports Reconfirmation of Glucose Lowering in Diabetes Clinical Trial and Initiation of Second Phase III Study
7/31/1995 Amylin Pharmaceuticals Initiates Phase III Studies of Pramlintide, an Experimental Diabetes Medicine;Announces Second Quarter Results
6/21/1995 Amylin Pharmaceuticals Announces Worldwide Diabetes Collaboration with the Lifescan Subsidiary of Johnson&Johnson
6/21/1995 Amylin Pharmaceuticals and Glaxo-Wellcome Announce Discontinuance of Research & Development Collaboration
5/15/1995 Amylin Pharmaceuticals Announces $10.8 Million Offering, First Quarter Results
2/27/1995 Amylin Pharmaceuticals Announces Successful Diabetes Clinical Trial; 1994 Financial Results
1/10/1995 Amylin Reports Expansion of Therapeutic Potential of AC137 to Type II Diabetics Who Use Insulin

CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer - (858) 552-2200